The intersection of substance use with broader public health concerns.
Public Health
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non–Small Cell Lung Cancer
Abstract Importance There is a need to tailor treatments to patients who are most likely to derive the greatest benefit from them to improve patient outcomes and enhance cost-effectiveness of cancer therapies. Objective To compare overall...
Variations in national availability of waivered buprenorphine prescribers by racial and ethnic composition of zip codes
Background Opioid overdose remains a public health crisis in diverse communities. Between 2019 and 2020, there was an almost 40% increase in drug fatalities primarily due to opioid analogues of both stimulants and opioids. Medications for...
A qualitative study exploring how young people perceive and experience substance use services in British Columbia, Canada
Background Substance use among youth (ages 12–24) is troublesome given the increasing risk of harms associated. Even more so, substance use services are largely under utilised among youth, most only accessing support when in crisis. Few...
Clearing the Smoke on Cannabis: Cannabis Use During Pregnancy and Breastfeeding
This report presents the latest clinical evidence on how cannabis use during pregnancy and breastfeeding can affect a developing fetus and infant. Key points include: the effects of cannabis can be passed onto the fetus through the placenta...
Effect of Community Support on the Implementation of Primary Health Care-Based Measurement of Alcohol Consumption
Abstract Alcohol measurement delivered by health care providers in primary health care settings is an efficacious and cost-effective intervention to reduce alcohol consumption among patients. However, this intervention is not yet routinely...
New Psychoactive Substances (NPS): Synthetic Hallucinogens/ Synthetic Depressants
The Second Webinar was hosted by ISSUP Pakistan and focus on Synthetic Hallucinogens/ Synthetic Depressants.
New Psychoactive Substances (NPS): Synthetic Hallucinogens/ Synthetic Depressants
ISSUP welcomes all members and colleagues involved in the drug demand reduction field to join our new webinar initiative – a series on New Psychoactive Substances (NPS).
The cardiovascular risks and benefits of quit smoking medicines
In this presentation, the speakers will report the results of a series of three population-based cohort studies relating to the use and effects of smoking cessation pharmacotherapies. The first of these studies provides evidence on how the three smoking cessation pharmacotherapies available in Australia (nicotine replacement therapy, varenicline and bupropion) compare to each other in terms of cardiovascular safety.
Is fetal brain monoamine oxidase inhibition the missing link between maternal smoking and conduct disorders?
Abstract Smoking is the leading cause of preventable illness in the world today. Prenatal cigarette smoke exposure (PCSE) is a particularly insidious form because so many of its associated health effects befall the unborn child and produce...